Technology transfer / Localization · GCC · Announced 22 Nov 2025

Local Content and Government Procurement Authority → AJA Pharma

Saudi Arabia's LCGPA signed a localisation agreement with AJA Pharma for ticagrelor, used to reduce heart attack and stroke risk, with an expected GDP contribution of up to SAR 110 million.

Parties: Local Content and Government Procurement Authority (LCGPA) (Saudi Arabia) → AJA Pharma (Saudi Arabia)

Value
See terms
Territory
Saudi Arabia
Therapeutic area
Cardiovascular
Asset
Ticagrelor
Announced
22 Nov 2025

Our analysis

Why this matters

On 22 November 2025, Saudi Arabia's Local Content and Government Procurement Authority (LCGPA) announced a localisation agreement with AJA Pharma for ticagrelor, an antiplatelet used to reduce the risk of heart attack and stroke. The agreement includes transfer of technical know-how. LCGPA said the product was added to its mandatory list after all localisation requirements were met, and estimated an expected contribution to GDP of up to SAR 110 million. That figure is an economic-return estimate, not a contract value.

Inclusion on the mandatory list gives the locally made product preference in government procurement.

The full analysis is free to read with a work email on this page.

Source: Souq Al Dawaa Saudi (citing LCGPA)

More deals involving Local Content and Government Procurement Authority or AJA Pharma

Latest deals

All GCC deals → · All technology transfer / localization deals → · Browse all emerging-market pharma deals →